Measuring minimal residual disease in chronic myeloid leukemia: fluorescence in situ hybridization and polymerase chain reaction.

Clinical lymphoma & myeloma

Volumn 9 Suppl 3, Issue , 2009, Pages

  Hughes, Timothy P ^a   Branford, Susan ^a  

^a INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN;

BONE MARROW CELL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; IN SITU HYBRIDIZATION; METABOLISM; METHODOLOGY; MINIMAL RESIDUAL DISEASE; NUCLEOTIDE SEQUENCE; ONCOLOGY; POLYMERASE CHAIN REACTION; REVIEW; TIME; TREATMENT OUTCOME;

BONE MARROW CELLS; CLINICAL TRIALS AS TOPIC; CYTOGENETICS; DNA MUTATIONAL ANALYSIS; FUSION PROTEINS, BCR-ABL; HUMANS; IN SITU HYBRIDIZATION; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MEDICAL ONCOLOGY; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; TIME FACTORS; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 74049131747     PISSN: None     EISSN: 19380712     Source Type: Journal    
DOI: 10.3816/clm.2009.s.022     Document Type: Review

References (55)